Search Results - "Petris, Luigi"

Caring for patients with cancer in the COVID-19 era by van de Haar, Joris, Hoes, Louisa R., Coles, Charlotte E., Seamon, Kenneth, Fröhling, Stefan, Jäger, Dirk, Valenza, Franco, de Braud, Filippo, De Petris, Luigi, Bergh, Jonas, Ernberg, Ingemar, Besse, Benjamin, Barlesi, Fabrice, Garralda, Elena, Piris-Giménez, Alejandro, Baumann, Michael, Apolone, Giovanni, Soria, Jean Charles, Tabernero, Josep, Caldas, Carlos, Voest, Emile E.

“…The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions…”
Get full text

Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis by Palma, David A., MD, MSc, PhD, Senan, Suresh, MRCP, FRCR, PhD, Tsujino, Kayoko, MD, Barriger, Robert B., MD, Rengan, Ramesh, MD, PhD, Moreno, Marta, MD, Bradley, Jeffrey D., MD, Kim, Tae Hyun, MD, Ramella, Sara, MD, Marks, Lawrence B., MD, De Petris, Luigi, MD, PhD, Stitt, Larry, MSc, Rodrigues, George, MD, MSc

“…Background Radiation pneumonitis is a dose-limiting toxicity for patients undergoing concurrent chemoradiation therapy (CCRT) for non-small cell lung cancer…”
Get full text

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer by Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, De Petris, Luigi, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C, Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Zeaiter, Ali, Shaw, Alice T

“…Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and…”
Get more information

Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC by Kilvaer, Thomas Karsten, Rakaee, Mehrdad, Hellevik, Turid, Vik, Jørg, Petris, Luigi De, Donnem, Tom, Strell, Carina, Ostman, Arne, Busund, Lill-Tove Rasmussen, Martinez-Zubiaurre, Inigo

“…Preclinical evidence suggests that stromal expression of platelet-derived growth factor receptors (PDGFRs) stimulates tumor development and diminishes…”
Get full text

Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study by Marzano, Luca, Darwich, Adam S., Dan, Asaf, Tendler, Salomon, Lewensohn, Rolf, De Petris, Luigi, Raghothama, Jayanth, Meijer, Sebastiaan

“…The potential of real‐world data to inform clinical trial design and supplement control arms has gained much interest in recent years. The most common approach…”
Get full text

Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting by Skribek, Marcus, Rounis, Konstantinos, Makrakis, Dimitrios, Agelaki, Sofia, Mavroudis, Dimitris, De Petris, Luigi, Ekman, Simon, Tsakonas, Georgios

“…There is lack of data addressing the intracranial (IC) efficacy of immune checkpoint inhibitors (ICIs) on brain metastases (BM) in non-small cell lung cancer…”
Get full text

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study by Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chih-Hsin, Hughes, Brett, Lena, Hervé, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Monnet, Annabelle, Zeaiter, Ali, Kim, Dong-Wan

“…Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer…”
Get full text

A gene expression‐based single sample predictor of lung adenocarcinoma molecular subtype and prognosis by Liljedahl, Helena, Karlsson, Anna, Oskarsdottir, Gudrun N., Salomonsson, Annette, Brunnström, Hans, Erlingsdottir, Gigja, Jönsson, Mats, Isaksson, Sofi, Arbajian, Elsa, Ortiz‐Villalón, Cristian, Hussein, Aziz, Bergman, Bengt, Vikström, Anders, Monsef, Nastaran, Branden, Eva, Koyi, Hirsh, Petris, Luigi, Patthey, Annika, Behndig, Annelie F., Johansson, Mikael, Planck, Maria, Staaf, Johan

“…Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for risk stratification beyond tumor stage are needed. Gene…”
Get full text

Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies by Rounis, Konstantinos, Makrakis, Dimitrios, Gioulbasanis, Ioannis, Ekman, Simon, De Petris, Luigi, Mavroudis, Dimitris, Agelaki, Sofia

“…Cancer cachexia syndrome (CCS) is a multifactorial metabolic syndrome affecting a significant proportion of patients. CCS is characterized by progressive…”
Get full text

A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer by Karlsson, Anna, Cirenajwis, Helena, Ericson-Lindquist, Kajsa, Brunnström, Hans, Reuterswärd, Christel, Jönsson, Mats, Ortiz-Villalón, Cristian, Hussein, Aziz, Bergman, Bengt, Vikström, Anders, Monsef, Nastaran, Branden, Eva, Koyi, Hirsh, de Petris, Luigi, Micke, Patrick, Patthey, Annika, Behndig, Annelie F., Johansson, Mikael, Planck, Maria, Staaf, Johan

“…Accurate histological classification and identification of fusion genes represent two cornerstones of clinical diagnostics in non-small cell lung cancer…”
Get full text

Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia by Björn, Niclas, Sigurgeirsson, Benjamín, Svedberg, Anna, Pradhananga, Sailendra, Brandén, Eva, Koyi, Hirsh, Lewensohn, Rolf, de Petris, Luigi, Apellániz-Ruiz, Maria, Rodríguez-Antona, Cristina, Lundeberg, Joakim, Gréen, Henrik

“…Chemotherapy-induced myelosuppression, including thrombocytopenia, is a recurrent problem during cancer treatments that may require dose alterations or…”
Get full text

Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer by Warner, Andrew, MSc, Dahele, Max, MBChB, PhD, FRCP, FRCR, Hu, Bo, MSc, Palma, David A., MD, PhD, FRCPC, Senan, Suresh, MRCP, FRCR, PhD, Oberije, Cary, MSc, PhD, Tsujino, Kayoko, MD, PhD, Moreno-Jimenez, Marta, MD, PhD, Kim, Tae Hyun, MD, Marks, Lawrence B., MD, Rengan, Ramesh, MD, PhD, De Petris, Luigi, MD, PhD, Ramella, Sara, MD, De Ruyck, Kim, PhD, De Dios, Núria Rodriguez, MD, PhD, Bradley, Jeffrey D., MD, Rodrigues, George, MD, PhD, FRCPC

“…Purpose Concurrent chemoradiation therapy (con-CRT) is recommended for fit patients with locally advanced non-small cell lung cancer (LA-NSCLC) but is…”
Get full text

Author Correction: Caring for patients with cancer in the COVID-19 era by van de Haar, Joris, Hoes, Louisa R., Coles, Charlotte E., Seamon, Kenneth, Fröhling, Stefan, Jäger, Dirk, Valenza, Franco, de Braud, Filippo, De Petris, Luigi, Bergh, Jonas, Ernberg, Ingemar, Besse, Benjamin, Barlesi, Fabrice, Garralda, Elena, Piris-Giménez, Alejandro, Baumann, Michael, Apolone, Giovanni, Soria, Jean Charles, Tabernero, Josep, Caldas, Carlos, Voest, Emile E.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer by Efazat, Ghazal, Novak, Metka, Kaminskyy, Vitaliy O, De Petris, Luigi, Kanter, Lena, Juntti, Therese, Bergman, Per, Zhivotovsky, Boris, Lewensohn, Rolf, Hååg, Petra, Viktorsson, Kristina

“…Ephrin receptors (Ephs) are reported to control metastatic signaling of non-small cell lung cancer (NSCLC) and other tumors. Here we show for the first time…”
Get full text

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy by Tendler, Salomon, Kanter, Lena, Lewensohn, Rolf, Ortiz-Villalón, Cristian, Viktorsson, Kristina, De Petris, Luigi

“…The aim was to analyse the tumor expression of Notch1, Hes1, Ascl1, and DLL3 in Small-Cell Lung Cancer (SCLC) and each such biomarker's potential association…”
Get full text

Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib by Morcos, Peter N., Cleary, Yumi, Guerini, Elena, Dall, Georgina, Bogman, Katrijn, Petris, Luigi, Viteri, Santiago, Bordogna, Walter, Yu, Li, Martin‐Facklam, Meret, Phipps, Alex

“…The efficacy and safety of alectinib, a central nervous system–active and selective anaplastic lymphoma kinase (ALK) inhibitor, has been demonstrated in…”
Get full text

miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression by Salim, Hogir, Arvanitis, Alexandros, de Petris, Luigi, Kanter, Lena, Hååg, Petra, Zovko, Ana, Özata, Deniz Mahmut, Lui, Weng-Onn, Lundholm, Lovisa, Zhivotovsky, Boris, Lewensohn, Rolf, Viktorsson, Kristina

“…The prognosis of non‐small cell lung cancer (NSCLC) is poor, since it has often metastasized to distant organs by the time of diagnosis. Therefore, biomarkers…”
Get full text

Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression by Hydbring, Per, De Petris, Luigi, Zhang, Yanming, Brandén, Eva, Koyi, Hirsh, Novak, Metka, Kanter, Lena, Hååg, Petra, Hurley, James, Tadigotla, Vasisht, Zhu, Baoli, Skog, Johan, Viktorsson, Kristina, Ekman, Simon, Lewensohn, Rolf

“…•Pleural effusions provide an abundant source for liquid biopsy RNA-profiling.•Exosomal derived microRNAs provide superior diagnostic value compared to…”
Get full text

Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non–Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis by Rodrigues, George, MD, PhD, FRCPC, Oberije, Cary, MSc, PhD, Senan, Suresh, MRCP, FRCR, PhD, Tsujino, Kayoko, MD, PhD, Wiersma, Terry, MD, Moreno-Jimenez, Marta, MD, PhD, Kim, Tae Hyun, MD, Marks, Lawrence B., MD, Rengan, Ramesh, MD, PhD, De Petris, Luigi, MD, PhD, Ramella, Sara, MD, DeRuyck, Kim, PhD, De Dios, Núria Rodriguez, MD, PhD, Warner, Andrew, MSc, Bradley, Jeffrey D., MD, Palma, David A., MD, PhD, FRCPC

“…Purpose The clinical benefits and risks of dose escalation (DE) for stage III non–small-cell lung cancer (NSCLC) remain uncertain despite the results from…”
Get full text

PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer by Dan, Asaf, Aricak, Ozan, Rounis, Konstantinos, Montero-Fernandez, M Angeles, Guijarro, Ricardo, Ekman, Simon, Ortiz-Villalón, Cristian, De Petris, Luigi

“…Programmed death ligand - 1 (PD-L1) expression is a well-established predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). Programmed…”
Get full text